587880-25-9

Usage

Uses

Used in Chemical Research:
Carbamic acid, [4-(4-hydroxyphenyl)butyl]-, phenylmethyl ester is used as a research compound for studying its chemical properties, reactivity, and potential applications in various fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Carbamic acid, [4-(4-hydroxyphenyl)butyl]-, phenylmethyl ester may be used as an intermediate in the synthesis of pharmaceutical compounds or as a building block for the development of new drugs.
Used in Agrochemical Industry:
Carbamic acid, [4-(4-hydroxyphenyl)butyl]-, phenylmethyl ester could be employed in the agrochemical industry as a precursor for the synthesis of pesticides or other agrochemical products.
Used in Material Science:
In material science, Carbamic acid, [4-(4-hydroxyphenyl)butyl]-, phenylmethyl ester may be utilized in the development of new materials with specific properties, such as polymers, coatings, or adhesives, due to its unique chemical structure.

Upstream product

• 501-53-1 benzyl chloroformate 
• 583825-27-8 1-(4-azidobutyl)-4-methoxybezene 
• 52244-70-9 4-(4-methoxyphenyl)butan-1-ol 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 72457-26-2 4-(4-Methoxyphenyl)butylamine 
• 2222-15-3 4-(4-Methoxyphenyl)-butyramide 
• 81786-51-8 1-methanesulfonyloxy-4-(4-methoxyphenyl)butane 
• 123-91-1 1,4-dioxane 

Downstream Products

• 905293-40-5 3-[4-(4-benzyloxycarbonylamino-butyl)-phenoxy]-propionic acid 
• 587880-36-2 {4-[4-((R)-2,3-Dihydroxy-propoxy)-phenyl]-butyl}-carbamic acid benzyl ester 
• 587880-38-4 {4-[4-((S)-2,3-Dihydroxy-propoxy)-phenyl]-butyl}-carbamic acid benzyl ester 
• 587880-27-1 N-Cbz-4-[4-(2,3-dihydroxypropyloxyl)phenyl]butylamine 
• 847201-20-1 (4-{4-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]phenyl}butyl)carbamic acid benzyl ester 
• 847201-16-5 (4-{4-[(carbamoylmethylcarbamoyl)methoxy]phenyl}butyl)carbamic acid benzyl ester 
• 847200-96-8 {4-[4-(3-cyanopropoxy)phenyl]butyl}carbamic acid benzyl ester 
• 876131-12-3 3-[4-(4-benzyloxycarbonylaminobutyl)phenoxy]-2-(tritylamino)propionic acid methyl ester 
• 876131-16-7 4-[4-(4-Benzyloxycarbonylaminobutyl)phenoxy]-2-tert-butoxycarbonylamino-butyric acid methyl ester 
• 587880-33-9 N-Cbz-4-[4-(1,4-Dioxapent-1-yl)phenyl]butylamine 
• 587880-40-8 4-[4-(1,4,7-Trioxaoct-1-yl)phenyl]-N-benzyloxycarbonylbutylamine 
• 587880-42-0 4-[4-(1,4,7,10,13-pentoxatetradec-1-yl)phenyl]-N-benzyloxycarbonylbutylamine 
• 742102-29-0 {4-[4-(2-Dimethylaminoethoxy)phenyl]butyl}carbamic acid benzyl ester 
• 587880-74-8 [4-(4-Benzyloxycarbonylaminobutyl)phenoxy]acetic acid ethyl ester 

Relevant academic research and scientific papers

SODIUM CHANNEL BLOCKERS

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: Drugs for cystic fibrosis and chronic bronchitis

Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent short-circuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloríde and displayed the lowest IC50 value ever reported for an ENaC blocker.

Sodium channel blockers

The present invention relates to sodium channel blockers. The present invention also relates to a variety of methods of treatment using the sodium channel blockers.